Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization time 7% Improvement Relative Risk Viral clearance time 55% Favipiravir  Shinada et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 34 patients in Japan (May - September 2020) Faster viral clearance with favipiravir (p=0.039) Shinada et al., Viruses, March 2022 Favors favipiravir Favors control

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

Shinada et al., Viruses, doi:10.3390/v14040670
Mar 2022  
  Source   PDF   All   Meta
Retrospective 17 COVID+ patients treated with favipiravir and 17 matched controls in Japan, showing faster viral clearance with treatment. Favipiravir 3600mg day one, 1600mg per day for up to 14 days.
hospitalization time, 7.5% lower, HR 0.93, p = 0.84, treatment 17, control 17.
viral clearance time, 55.2% lower, HR 0.45, p = 0.04, treatment 17, control 17.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shinada et al., 24 Mar 2022, retrospective, Japan, peer-reviewed, 11 authors, study period 28 May, 2020 - 26 September, 2020, average treatment delay 8.9 days. Contact: (corresponding author),,,,,,,,,,
This PaperFavipiravirAll
Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir
Kanako Shinada, Takashi Sato, Saya Moriyama, Yu Adachi, Masahiro Shinoda, Shinichiro Ota, Miwa Morikawa, Masamichi Mineshita, Takayuki Matsumura, Yoshimasa Takahashi, Masaharu Shinkai
Viruses, doi:10.3390/v14040670
The effect of treatment with favipiravir, an antiviral purine nucleoside analog, for coronavirus disease 2019 (COVID-19) on the production and duration of neutralizing antibodies for SARS-CoV-2 was explored. There were 17 age-, gender-, and body mass index-matched pairs of favipiravir treated versus control selected from a total of 99 patients recovered from moderate COVID-19. These subjects participated in the longitudinal (>6 months) analysis of (i) SARS-CoV-2 spike protein's receptor-binding domain IgG, (ii) virus neutralization assay using authentic virus, and (iii) neutralization potency against original (WT) SARS-CoV-2 and cross-neutralization against B.1.351 (beta) variant carrying triple mutations of K417N, E484K, and N501Y. The results demonstrate that the use of favipiravir: (1) significantly accelerated the elimination of SARS-CoV-2 in the case vs. control groups (p = 0.027), (2) preserved the generation and persistence of neutralizing antibodies in the host, and (3) did not interfere the maturation of neutralizing potency of anti-SARS-CoV-2 and neutralizing breadth against SARS-CoV-2 variants. In conclusion, treatment of COVID-19 with favipiravir accelerates viral clearance and does not interfere the generation or maturation of neutralizing potency against both WT SARS-CoV-2 and its variants.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Tokyo Shinagawa Hospital (approval number 20-A-08 and approved on 20 May 2020). Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Alqahtani, Oyelade, Aldhahir, Alghamdi, Almehmadi et al., Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis, PLoS ONE, doi:10.1371/journal.pone.0233147
Altay, Mohammadi, Lam, Turkez, Boren et al., Current Status of COVID-19 Therapies and Drug Repositioning Applications, iScience, doi:10.1016/j.isci.2020.101303
Bosnjak, Stein, Willenzon, Cordes, Puppe et al., Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods, Cell. Mol. Immunol, doi:10.1038/s41423-020-00573-9
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering, doi:10.1016/j.eng.2020.03.007
Clinicaltrials, Gov, Favipiravir for Patients With Mild to Moderate Disease from Novel Coronavirus (COVID-19
Doi, Hibino, Hase, Yamamoto, Kasamatsu et al., Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19, Antimicrob. Agents Chemother, doi:10.1128/AAC.01897-20
Edalatifard, Akhtari, Salehi, Naderi, Jamshidi et al., Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial, Eur. Respir. J, doi:10.1183/13993003.02808-2020
Fujifilm, Fujifilm Announces the Start of a New Phase III Clinical Trial of Anti-Influenza Drug Avigan®Tablet in Japan, Targeting COVID-19 Patients
Garcia-Beltran, Lam, Astudillo, Yang, Miller et al., COVID-19-neutralizing antibodies predict disease severity and survival, Cell, doi:10.1016/j.cell.2020.12.015
Gluck, Grobecker, Tydykov, Salzberger, Gluck et al., SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19, Infection, doi:10.1007/s15010-021-01598-6
Goto, Go, Miyakawa, Yamaoka, Ohtake et al., Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors, Front. Microbiol, doi:10.3389/fmicb.2021.661187
Gottlieb, Nirula, Chen, Boscia, Heller et al., Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2021.0202
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials, Sci. Rep
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in Hospitalized Patients with COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2021436
Jeronimo, Farias, Val, Sampaio, Alexandre et al., Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease, Viruses
Lau, Tsang, Hui, Kwan, Chan et al., Neutralizing antibody titres in SARS-CoV-2 infections, Nat. Commun, doi:10.1038/s41467-020-20247-4
Marois, Cloutier, Garneau, Lesur, Richter, The administration of oseltamivir results in reduced effector and memory CD8+ T cell responses to influenza and affects protective immunity, FASEB J, doi:10.1096/fj.14-260687
Metcovid, A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial, Clin. Infect. Dis
Moriyama, Adachi, Sato, Tonouchi, Sun et al., Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants, Immunity, doi:10.1016/j.immuni.2021.06.015
Ong, Chiew, Ang, Mak, Cui et al., Clinical and virological features of SARS-CoV-2 variants of concern: A retrospective cohort study comparing B.1.1.7, Clin. Infect. Dis, doi:10.1093/cid/ciab721
Ranjbar, Moghadami, Mirahmadizadeh, Fallahi, Khaloo et al., Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial, BMC Infect. Dis, doi:10.1186/s12879-021-06045-3
Salton, Confalonieri, Meduri, Santus, Harari et al., Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia, Open Forum Infect. Dis
Shinahara, Takahashi, Sawabuchi, Arai, Hirotsu et al., Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: A retrospective analysis, PLoS ONE, doi:10.1371/journal.pone.0070060
Shinkai, Tsushima, Tanaka, Hagiwara, Tarumoto et al., Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial, Infect. Dis. Ther, doi:10.1007/s40121-021-00517-4
Takahashi, Kataoka, Fujii, Chida, Mizuno et al., Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus, Microbes Infect, doi:10.1016/j.micinf.2010.04.013
Tegally, Wilkinson, Giovanetti, Iranzadeh, Fonseca et al., Detection of a SARS-CoV-2 variant of concern in South Africa, Nature, doi:10.1038/s41586-021-03402-9
Torjesen, COVID-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear, BMJ, doi:10.1136/bmj.n2943
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.142
Volz, Mishra, Chand, Barrett, Johnson et al., Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England, Nature, doi:10.1038/s41586-021-03470-x
Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2035002
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4
Wu, Liang, Chen, Wang, Fang et al., SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19, Nat. Commun, doi:10.1038/s41467-021-22034-1
Yu, Tostanoski, Peter, Mercado, Mcmahan et al., DNA vaccine protection against SARS-CoV-2 in rhesus macaques, Science, doi:10.1126/science.abc6284
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop